Profiles of B-cell subsets in immunologically stable renal allograft recipients and end-stage renal disease patients
Profiles of B-cell subsets in immunologically stable renal allograft recipients and end-stage renal disease patients
复制标题
免疫稳定的同种异体肾移植受者和终末期肾病患者的 B 细胞亚群概况
DOI：
10.1016/j.trim.2019.101249
复制
发表时间：
2020-02-01
影响因子：
1.5
通讯作者：
Ming, Yingzi
中科院分区：
文献类型：
--
作者：
Zhuang, Quan;Li, Hao;Ming, Yingzi
背景：移植后药物治疗通常采用免疫抑制剂的组合，这些药物旨在靶向抑制 T 细胞和 T 细胞亚群。临床上使用的免疫抑制剂对细胞和细胞亚群的急性和慢性影响的研究数量明显较少，值得进一步研究。因此，本横断面研究的目标是从功能上评估终末期肾病 (ESRD) 患者和免疫学稳定的肾移植患者中 B 细胞亚群的差异。 患者和方法：在 103 名接受肾移植的患者中，73 名患者免疫学稳定，没有排斥或感染。其中，34名患者为移植后一年，39名患者为移植后五年。该研究还包括 35 名 ESRD 患者和 36 名健康志愿者。流式细胞术鉴定了研究组中的细胞亚群。结果：与健康对照相比，同种异体肾移植受者的总 B 细胞 (CD19 +) 和调节细胞 (B-reg) (CD38(高)CD27 + CD24 +) 的百分比降低。与 ESRD 患者和健康志愿者相比，移植受者的移行细胞（IgM + CD38（高）CD24（高））和边缘区 (MZ) B 细胞 (IgD-CD27 +) 的百分比降低。 ESRD 患者的浆细胞 (PC) (CD38(高)CD27 + CD24-) 百分比最高。移植后五年组中，CD38（低）CD21-B 细胞与其他组相比有所增加。健康志愿者和 ESRD 患者的未转换记忆 (UM) 细胞 (IgM + IgD + CD38(低)CD27 +) 较少，同种型转换记忆 (ISM) 细胞 (IgM-IgD-CD38(低)CD27 +) 增加。不同组间初始 B 细胞 (IgD + CD27-) 的百分比没有差异。结论：免疫稳定的同种异体肾移植受者中总细胞、过渡细胞、Bres、PC、MZ 和 UM 细胞亚群的百分比与健康对照显着不同。然而，ESRD 患者的 B 细胞亚群与免疫稳定的同种异体肾移植受者的差异极小。
Background: Post-transplantation pharmacotherapies typically employ combinations of immunosuppressive agents that have been designed for targeted inhibition of T-cells and T-cell subsets. Studies of acute and chronic effects of clinically employed immunosuppressive agents on-cells and-cell subsets are significantly fewer in number and warrant further investigation. Accordingly, the goal of the present cross-sectional study is to functionally evaluate differences of B-cell subsets in patients with end-stage renal disease (ESRD) and immunologically stable renal transplant patients.Patients and methods: Of 103 patients who underwent renal transplantation, 73 patients were immunologically stable without rejection or infection. Among them, 34 patients were one-year post-transplantation, and 39 patients were five-year post-transplantation. The study also included 35 ESRD patients and 36 healthy volunteers. Flow cytometry identified-cell subsets in the study groups.Results: Renal allograft recipients had reduced percentages of total B-cells (CD19 +) and regulatory-cells (B-reg) (CD38(high)CD27 + CD24 +) compared with healthy controls. The percentage of transitional-cells (IgM + CD38(high)CD24(high)) and marginal zone (MZ) B-cells (IgD-CD27 +) was reduced in transplant recipients compared with patients with ESRD and healthy volunteers. The highest percentage of plasma cells (PCs) (CD38(high)CD27 + CD24-) was in patients with ESRD. In five-year post-transplantation group, CD38(low)CD21-B-cells increased when compared with the other groups. Healthy volunteers and patients with ESRD had fewer unswitched memory (UM)-cells (IgM + IgD + CD38(low)CD27 +), and increased isotype switched memory (ISM)-cells (IgM-IgD-CD38(low)CD27 +). There was no difference in the percentage of naive B-cells (IgD + CD27-) among diverse groups.Conclusions: The percentages of the total, transitional, Bres, PCs, MZ, and UM-cell subsets in immunologically stable renal allograft recipients were significantly different from healthy controls. However, B-cell subsets in patients with ESRD were minimally different with immunologically stable renal allograft recipients.